Mycophenolate is a commonly used immunosuppressant to prevent organ rejection in transplant recipients. It is also used as an immunosuppressant in other disciplines, such as rheumatology. While mycophenolate has been available for decades – it remains the focus of an ongoing FDA Risk Evaluation and Mitigation Strategy (REMS) program due to the high probability for fetal teratogenicity during pregnancy. Congenital malformations in children born to mothers taking mycophenolate have included hearing loss, cleft palate, heart defect, and various other malformations of the face, head, kidneys, limbs, and esophagus.
Currently, the importance of pregnancy planning and/or prevention is even more critical than in previous years. As of August 2023, twenty-two states ban abortion or restrict the procedure earlier in pregnancy than the standard set by Roe v. Wade for the past 50 years, which was overturned by the Supreme Court in 2022. Thus, as the title of this education initiative states — adherence to the mycophenolate REMS (MREMS) program is of paramount importance — now more than ever.
Please join an expert multidisciplinary faculty in a compelling live and on-demand webcast on how to effectively implement MREMS in clinical practice. As a bonus feature, you’ll also be able to participate in an engaging MREMS “Clinical Clues” Escape Room activity to further reinforce the importance of pregnancy planning and/or prevention when using mycophenolate in women of childbearing potential.
This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Transplant medicine specialists, OB/GYNs, surgeons, rheumatologists, dermatologists, immunologists, cardiologists, primary care practioners (PCPs), nurse practitioners (NPs), physician associates (PAs), nurses, dentists, optometrists, psychologists, and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit ( JA0007185-0000-23-103-H01-P ).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 11/08/2024. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
The AAFP has reviewed this activity and deemed it acceptable for up to 1.00 Enduring Material AAFP Prescribed credits. Term of approval is from 11/08/2023 to 11/08/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Winterstein reports the following financial relationships:
Consultant: Bayer; Genentech, Inc.; Ipsen Biopharmaceuticals, Inc.; and Merck & Co., Inc.
Dr. Cintron reports no financial relationships to disclose.
Dr. Kim reports no financial relationships to disclose.
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
WCV-076-110823-62
